Compare R & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | R | RDY |
|---|---|---|
| Founded | 1933 | 1984 |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | Rental/Leasing Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6B | 9.9B |
| IPO Year | 1994 | 2001 |
| Metric | R | RDY |
|---|---|---|
| Price | $238.29 | $12.50 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 11 | 5 |
| Target Price | ★ $288.33 | $13.22 |
| AVG Volume (30 Days) | 207.4K | ★ 2.9M |
| Earning Date | 10-22-2026 | 10-23-2026 |
| Dividend Yield | ★ 1.72% | 0.53% |
| EPS Growth | ★ 7.96 | N/A |
| EPS | ★ 5.71 | N/A |
| Revenue | ★ $12,665,000,000.00 | N/A |
| Revenue This Year | $4.88 | $4.75 |
| Revenue Next Year | $5.10 | $11.72 |
| P/E Ratio | $41.19 | ★ $18.67 |
| Revenue Growth | ★ 0.23 | N/A |
| 52 Week Low | $157.77 | $11.36 |
| 52 Week High | $284.25 | $15.67 |
| Indicator | R | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 48.57 | 54.24 |
| Support Level | $224.11 | $12.09 |
| Resistance Level | $250.96 | $12.48 |
| Average True Range (ATR) | 5.04 | 0.22 |
| MACD | 0.95 | -0.00 |
| Stochastic Oscillator | 81.65 | 48.00 |
Ryder System Inc operates in three business segments: (1) Fleet Management Solutions which provides full-service leasing and leasing with flexible maintenance options, commercial rental and maintenance services of trucks, tractors and trailers to customers; (2) Supply Chain Solutions (SCS), which provides integrated logistics solutions, including distribution management, dedicated transportation, transportation management, brokerage, e-commerce, last mile, and professional services; and (3) Dedicated Transportation Solutions (DTS), which provides turnkey transportation solutions in the U.S., including dedicated vehicles, professional drivers, management, and administrative support.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.